HACKATAO X CRYPTO STAMP ART: AUSTRIAN POST PRESENTS NEW “CRYPTO STAMP ART” WITH SOULBOUND TOKEN AND AUTHENTICITY CERTIFICATE
Austrian Post issues its new Crypto stamp art (CSA). The limited special edition by renowned Italian artist duo Hackatao is immortalised and secured on the blockchain and it’s also the first time a Soulbound token has been used as a certificate of authenticity. Crypto stamp art focuses on works by renowned digital artists, making it a coveted collector’s item for crypto investors, art enthusiasts and philatelists.
INSPIRED BY AUSTRIAN HISTORY
The four motifs are inspired by Austrian history: Empress Sisi and Emperor Franz Joseph – each in a ‘living’ and ‘dead’ version. “In death, we are all equal”: This stamp combines Austrian tradition with modern technology and tells the story of a life full of tragedy, romance, and wanderlust.
The animated digital versions come in different rarity grades – from Danube Blue to Imperial Red. Particularly rare digital ‘misprints’ are also hidden in the collection. The physical and digital versions are forever linked by a Soulbound token, making a wallet-to-wallet transfer impossible.
CRYPTO-ART PIONEERS
“We were intrigued by this project because it allowed us to engage with something as institutional as the Postal Service and become part of the history of a form of collecting that runs parallel to the crypto art world. Being part of a collection that embodies such a rich history moved and inspired us. The Austrian Post is an OG in this NFT space, just as we are. They stand out as an institution and for its educational efforts, making the Web3 world more accessible to a traditional audience”, said artist duo Hackatao.
Available in selected post offices, the Crypto stamp online shop (shop.crypto.post.at/en) and via the collector’s service (phone: +43 577 67 – 95095; email: sammler-service@post.at).
More information: cryptostamp.com
Contacts
Press TeamAustrian Post
Tel:+435776732010presse@post.atImages
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Biomay Obtains FDA Approval for Manufacturing of Cas9 Nuclease at Headquarters Site29.4.2025 14:00:00 CEST | Press Release
The company announced its successful approval by the U.S. Food and Drug Administration (FDA) for the manufacturing, testing and release of recombinant Cas9 nuclease from its headquarters site. Cas9 is an essential component of CRISPR-based gene editing therapies, including CASGEVY® (exagamglogene autotemcel) developed and launched by Vertex Pharmaceuticals. Biomay's recent achievement refers to an inspection by the FDA's Center for Biologics Evaluation and Research (CBER) at Biomay's headquarters manufacturing site in Vienna, Seestadt in December 2024. No observation was found, and no Form FDA 483 was issued by the authority, allowing Biomay's headquarters site to supply Cas9 for the United States. Biomay operates two independent cGMP manufacturing sites, a headquarters facility in Vienna Seestadt, and a second site in Vienna downtown. The authority’s approval of Biomay's headquarters site represents the company's second successful FDA inspection following the 2023 approval of Biomay's
Growth and innovation as cornerstones of a strong democracy and a digitally sovereign Europe29.4.2025 12:00:00 CEST | Pressmeddelande
Germany should be restored to a growth path and should give new impulse to innovation, along with its European partners. Because prosperity is a significant guarantor of a stable democracy. Digital sovereignty is the anchor of a strong Europe. Germany can once again be a country of pioneering innovation and a pacesetter for the continent. For this, comprehensive modernization of the state is indispensable. The Bertelsmann Stiftung presented its proposals at the annual press conference.
Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study29.4.2025 09:00:00 CEST | Press Release
Tübingen, Germany, April 29, 2025 Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy.
Australia’s next government must mend structural cracks appearing in its political, economic and social foundation, report finds25.4.2025 12:05:00 CEST | Pressmeddelande
- Picture is available at AP - Los Angeles/DNA - Australia boasts some of the world’s most sophisticated political institutions and one of its wealthiest economies. But this veneer of success masks deeper structural issues — and a “ticking time bomb” of overreliance on extractive industries must be addressed under Australia’s next government, a new report recommends.
DYMO® LETRATAG 200B VINNER DET PRESTIGEFYLLDA PRISET ”BUSINESS PRODUCT OF THE YEAR” - STRUKTURERAR OCH ORGANISERAR VARDAGEN24.4.2025 16:44:06 CEST | Press Release
Amsterdam – vikten av organisering, effektivitet och produktivitet i både personliga och professionella sammanhang har aldrig varit större. Detta då allt fler använder smarta lösningar för att förenkla sin vardag. DYMO®, en ledande leverantör av innovativa etikett- och utskriftslösningar, ligger här i framkant. Som ett erkännande har DYMO LetraTag 200B belönats med EOPA Best Business Product Award, en utmärkelse som lyfter fram hur den förenklat organisering både hemma och på kontoret. "Trenden mot smart självorganisering fortsätter", berättar Liesbet De Soomer, Global Marketing Director på DYMO. "LetraTag 200B stödjer utveckligen genom att erbjuda en användarvänlig lösning, som gör märkningen snabb och enkel. Med det här verktyget kan användaren strukturera vardagskaoset och organisera tillvaron.” EOPA Best Business Product Award, som delas ut årligen, uppmärksammar produkter som sticker ut för sitt nytänkande, sin funktionalitet och sin användarvänlighet. LetraTag 200B:s utmärkelse b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom